menu
    • menu

    Company profile for Phyton Biotech LLC

    Phyton Biotech-PSE
    News
    Phyton Biotech recognized as a 2025 Life Sciences BC to Watch

    10 Jul 2025

    // PRESS RELEASE

    Phyton Biotech Named 2025 Life Sciences BC Company to Watch

    10 Jul 2025

    // PRESS RELEASE

    Phyton Biotech to attend CPHI China in Shanghai

    12 Jun 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Phyton Biotech

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://player.vimeo.com/video/364849942

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    SERVICES

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Related CompaniesRelated Companies

    About

    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and food industries. Facilities in Germany and Canada comply with international GMP requirements and have been inspected by multiple regulatory agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Phyton Biotech LLCCanada Flag
    Country
    Country
    Canada
    Address
    Address
    1503 Cliveden Avenue, Delta, BC V3M 6P7
    Telephone
    Telephone
    +1 6047772340
    Client Email
    Email
    api@phytonbiotech.com
    Client Website
    Website
    https://phytonbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/phyton-biotech
    youtube
    YouTube
    https://vimeo.com/user103692697
    Twitter
    Twitter
    https://x.com/PhytonBiotech
    Contact Info
    Others

    Email
    jackie.labbe@phytonbiotech.com

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    "Our PCF technology allows us a minimal environmental footprint while ensuring a sustainable supply of drugs"

    mic"Our PCF technology allows us a minimal environmental footprint while ensuring a sustainable supply of drugs"

    This week, SpeakPharma interviews Jackie Labbe, Vice-President, Sales & Marketing, Phyton Biotech, a global supplier of high-quality active pharmaceutical ingredients (APIs) made through plant cell fermentation (PCF). Paclitaxel and docetaxel are both taxanes. The two APIs have historically been derived from Pacific yew trees, and are used in the treatment of cancer. In the interview, Labbe talks about Phyton’s PCF technology, and how its scalability makes it a cost-competitive and sustainable alternative to traditional extraction manufacturing processes. — What is plant cell fermentation technology? How do you use it to make biotech APIs? And how is this technology cost-competitive? Plant cell fermentation (PCF) technology is the ability to use plant cells to make active chemical compounds that are typically extracted from plant biomass. Phyton uses this technology to produce various active pharmaceutical ingredients (APIs), while assuring a sustainable supply chain that does not depend on variations in climatic conditions, and also doesn’t lead to an exploitation of precious natural resources. The technology is scalable, while also being cost-competitive.  Using our PCF technology, we produce various cancer-fighting molecules like paclitaxel and docetaxel. Recently, we also entered into partnerships to develop various other compounds to ensure a sustainable supply of many new chemical entities. Since PCF technology is scalable, Phyton is able to expand production as and when required. This way, it is able to take advantage of economies of scale when our demand increases. The scalability of the PCF technology, along with its lack of dependence on the natural plant raw materials, makes it a cost-competitive alternative to traditional extraction manufacturing processes. — How has PCF helped overcome the supply chain challenges of taxanes and other natural products? Over the years, the growing demand for taxane APIs created significant pressure on the yew trees from which a key building block of these APIs had historically been derived. The over-exploitation of natural resources got to a point where trade of the Himalayan yew species was severely restricted. Phyton Biotech developed and applies sustainable and “green” chemistry manufacturing solutions for phytochemicals using PCF, which now serve the pharmaceutical as well as the traditional Chinese medicine (TCM), cosmetic, agricultural and food ingredient industries. By utilizing our revolutionary PCF platform, we are able to offer a time, risk, and cost-balanced path to commercially viable production processes. With certified GMP facilities in Germany and Canada, Phyton combines highly developed technology and quality that meets the needs of its global customers. We have a successful track record of developing and implementing innovative contract development solutions for clients around the world. Since Phyton has a yew tree cell bank, the company has complete control over the key starting ingredient.  This allows Phyton to function independent of cost fluctuations that may be attributed to starting ingredients used in traditional paclitaxel manufacturing process. The same principle applies to other natural products developed via PCF. — Tell us a little about the history of taxanes. The history of taxanes dates back to 1962, when a bark from the Pacific yew tree (Taxus brevifolia), was collected as part of the US National Cancer Institute (NCI) natural products screening program. Samples derived from this bark showed cytotoxic effects and it was not until 1977, when the NCI was able to confirm anti-tumor activity in mouse models. The active molecule was paclitaxel. It later became available under the brand name Taxol. Subsequent research has shown that taxanes worked in a completely different way from other cytotoxic drugs. Paclitaxel is now included on the World Health Organization’s Model List of Essential Medicines.  While initial commercial production of paclitaxel was achieved through direct extraction from the Pacific Yew, over time it became possible to manufacture the API using a precursor of paclitaxel, 10-deacetyl baccatin III, which was more widely available. In December 1992, the FDA approved Taxol for the treatment of ovarian cancer. — What are some of the regulatory challenges you face? And how are you able to comply with the regulatory standards and GMPs? Our paclitaxel is produced according to good manufacturing practices (GMPs) from the moment we remove a vial containing plant cells from the cryobank for production.  GMP is continued all the way through the fermentation and purification process, and until it is shipped to our customers as a finished API.  Both our paclitaxel and docetaxel are produced according to the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP) and our manufacturing facilities have been inspected and approved by all the leading global health authorities. Our APIs are also supported with Drug Master Files and Certificates of Suitability and we have successfully demonstrated to regulators the consistently high quality of our products.   — What are your future plans? How do you plan to take the PCF technology forward? Our aim is to expand the number of products produced by applying our plant cell fermentation to products in niche markets across pharmaceutical, traditional herbal medicines, food and nutrition and cosmetics. — In a world where sustainable supply of drugs is a big challenge, how can PCF help? Excellent question.  As you are aware, we are the global leaders in specialty fermentation, with the knowhow, expertise, and infrastructure to develop, scale up, and commercially manufacture phytochemicals and recombinant proteins via plant cell fermentation. PCF is definitely one of the ways to produce some drugs sustainably because the source of the active ingredient is produced independent of plant biomass.  As I mentioned before, PCF is scalable, so our entire production can be scaled up or down as needed with very minimal effort. This characteristic of our PCF technology makes us have a minimal environmental footprint while ensuring a sustainable supply of drugs that are cost-competitive.  

    Impressions: 3134

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-pcf-technology-makes-us-have-a-minimal-environmental-footprint-while-ensuring-a-sustainable-supply-of-drugs-speakpharma-with-phyton-biotech

    #SpeakPharma With Phyton Biotech
    12 Nov 2019
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-33670.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-53385.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-18048.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Contract Development and Commercial Manufacturing Capabilities

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-30962.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Supply Solutions via PCF® Technology

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-1626676037.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    China’s NMPA Approval for Phyton's Paclitaxel API

    read-more

      https://www.pharmacompass.com/pdf/party/content/phyton-biotech-llc-party-content-1623137732.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 14846

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Phyton Biotech recognized as a 2025 Life Sciences BC to Watch
    Phyton Biotech recognized as a 2025 Life Sciences BC to Watch

    10 Jul 2025

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-2025-life-sciences-bc-company-to-watch/

    PRESS RELEASE
    10 Jul 2025
    Share Share
    Phyton Biotech Named 2025 Life Sciences BC Company to Watch
    Phyton Biotech Named 2025 Life Sciences BC Company to Watch

    10 Jul 2025

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-2025-life-sciences-bc-company-to-watch/

    PRESS RELEASE
    10 Jul 2025
    Share Share
    Phyton Biotech to attend CPHI China in Shanghai
    Phyton Biotech to attend CPHI China in Shanghai

    12 Jun 2024

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-biotech-to-attend-cphi-china-shanghai-2/

    PRESS RELEASE
    12 Jun 2024
    Share Share
    Phyton Biotech’s Head of Cell Culture Developt will present 2024 World Congress
    Phyton Biotech’s Head of Cell Culture Developt will present 2024 World Congress

    09 Jun 2024

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-biotech-to-present-2024-world-congress-in-vitro-biology/

    PRESS RELEASE
    09 Jun 2024
    Share Share
    Phyton Biotech attends BIO International Convention 2024
    Phyton Biotech attends BIO International Convention 2024

    06 Jun 2024

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-biotech-to-attend-bio-international-convention/

    PRESS RELEASE
    06 Jun 2024
    Share Share
    Phyton Biotech to attend the 2024 Global Synthetic Biology Conference
    Phyton Biotech to attend the 2024 Global Synthetic Biology Conference

    06 May 2024

    // PRESS RELEASE

    https://phytonbiotech.com/phyton-biotech-to-attend-global-synthetic-biology-conference/

    PRESS RELEASE
    06 May 2024
    Share Share

    LISTED APIs

    read-more
    read-more
    Contact Supplier
    • FDA
    • EDQM
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Docetaxel

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and foo...
    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and food industries. Facilities in Germany and Canada comply with international GMP requirements and have been inspected by multiple regulatory agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Phyton Company Banner

    01

    Docetaxel

    Canada
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Phyton Biotech LLC

    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and food industries. Facilities in Germany and Canada comply with international GMP requirements and have been inspected by multiple regulatory agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    About the Company : Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It off...

    Phyton Company Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Contact Supplier
    • FDA
    • EDQM
    • Audit Compliance
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Paclitaxel

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and foo...
    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and food industries. Facilities in Germany and Canada comply with international GMP requirements and have been inspected by multiple regulatory agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Phyton Company Banner

    02

    Paclitaxel

    Canada
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Phyton Biotech LLC

    Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It offers integrated contract development and commercial manufacturing services from feasibility to production for pharmaceutical, cosmetic, agricultural, and food industries. Facilities in Germany and Canada comply with international GMP requirements and have been inspected by multiple regulatory agencies. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    About the Company : Phyton Biotech, a division of DFB Pharmaceuticals founded in 1990, is the world’s largest producer of high-quality paclitaxel and docetaxel using Plant Cell Fermentation technology. It off...

    Phyton Company Banner

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions

    Details:

    PellePharm’s patedigib topical gel is an investigational treatment to be used for rare dermatologic conditions. This is the first step in efforts to enable the renewable production of cyclopamine.


    Lead Product(s): Patidegib,Inapplicable

    Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Recipient: PellePharm

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 11, 2021

    Phyton Company Banner

    01

    Phyton Biotech LLC

    Canada
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothPhyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Lead Product(s) : Patidegib,Inapplicable

    Therapeutic Area : Rare Diseases and Disorders

    Highest Development Status : Phase III

    Recipient : PellePharm

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building B...

    Details : PellePharm’s patedigib topical gel is an investigational treatment to be used for rare dermatologic conditions. This is the first step in efforts to enable the renewable production of cyclopamine.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 11, 2021

    Phyton Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company

    Others

    read-more
    read-more

    ABOUT THIS PAGE

    Contact Phyton Biotech LLC and get a quotation

    Phyton Biotech LLC is a supplier offers 4 products (APIs, Excipients or Intermediates).

    Find a price of Docetaxel bulk with DMF, CEP, JDMF offered by Phyton Biotech LLC

    Find a price of Paclitaxel bulk with DMF, CEP, JDMF offered by Phyton Biotech LLC

    Find a price of Paclitaxel bulk with DMF offered by Phyton Biotech LLC

    Find a price of Paclitaxel bulk offered by Phyton Biotech LLC

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search